Thinking of Investing in TAK? What Our Analysts Know.

By Kim Brooks • Monday, January 16 15:02 • Permanent Link

Takeda Pharmaceutical Company logged a 2.3% change during today's afternoon session, and is now trading at a price of $16.1 per share. The S&P 500 index moved 0.4%. TAK's trading volume is 2,836,023 compared to the stock's average volume of 3,143,895.

Takeda Pharmaceutical Company trades -11.83% away from its average analyst target price of $18.26 per share. The 3 analysts following the stock have set target prices ranging from $13.98 to $24.86, and on average have given Takeda Pharmaceutical Company a rating of hold.

Anyone interested in buying TAK should be aware of the facts below:

Takeda Pharmaceutical Company's current price is -99.1% below its Graham number of $1787.05, which implies the stock has a margin of safety
Takeda Pharmaceutical Company has moved 10.7% over the last year, and the S&P 500 logged a change of -12.6%
Based on its trailing earnings per share of 0.52, Takeda Pharmaceutical Company has a trailing 12 month Price to Earnings (P/E) ratio of 31.0 while the S&P 500 average is 15.97
TAK has a forward P/E ratio of 8.1 based on its forward 12 month price to earnings (EPS) of $1.98 per share
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally.
Based in Tokyo, the company has 47,347 full time employees and a market cap of $50,055,708,672. Takeda Pharmaceutical Company currently returns an annual dividend yield of 1143.6%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.